CardioNexa is a managed lipid optimization service that identifies every patient falling short of their LDL-C target, prioritizes them by clinical urgency, and delivers specific therapy recommendations — so no patient falls through the cracks.
A complete managed service platform for ASCVD secondary prevention — from patient identification to therapy optimization to outcome tracking.
Every ASCVD patient scored and ranked by clinical urgency and impact. Your team works the highest-value patients first, every day.
Specific therapy recommendations citing the 2026 ACC/AHA guidelines — not generic advice. Actionable for each individual patient.
Morning command center showing today's priority patients with one-click actions: log calls, fax prior authorizations, copy EHR-ready notes.
Weekly population summary with therapy gap analysis, risk score distribution, and progress toward LDL-C goals across your ASCVD panel.
Natural language queries across your patient panel. "Show me patients with denied PAs" or "Who needs a PCSK9i?" — instant, accurate answers.
We handle data ingestion, clinical processing, and reporting. Your team reviews and acts on the recommendations. We measure the outcomes.
Only 45% of ASCVD patients meet their LDL-C targets. The issue isn't knowledge — it's execution. CardioNexa fixes the workflow.
EHR alerts fire and get ignored. CardioNexa generates executable, role-assigned tasks with specific therapy recommendations — not generic pop-ups.
Every recommendation traces through a clinical decision tree aligned with published guidelines. Physicians can audit the logic. No opaque ML models making clinical decisions.
Our CEO spent decades in cardiac surgery seeing what happens when lipids go unmanaged. This isn't a tech company guessing at healthcare — it's clinicians building what they needed.
LipidNova is CardioNexa's clinical decision engine — the technology behind our managed lipid services. It processes your ASCVD patient population through a deterministic, guideline-aligned decision tree and produces prioritized, actionable recommendations for every patient.
CardioNexa integrates with your existing workflow — no EHR overhaul required.
We securely ingest your ASCVD patient population via FHIR R4 or CSV extract from your EHR. Encrypted in transit and at rest. BAA signed before any data sharing.
Our decision engine evaluates every patient against the 2026 ACC/AHA therapy ladder — risk stratification, LDL target determination, gap identification, and therapy optimization. Every recommendation is auditable.
Your team receives a prioritized workqueue with specific, patient-level recommendations. Daily digest highlights the highest-urgency cases. Weekly executive reports track population progress.
Pharmacists review and act on recommendations with one-click EHR note copy, PA tracking, and activity logging. Actioned patients enter a 90-day follow-up cycle automatically.
CardioNexa was founded by a cardiac surgeon and a technologist who saw the gap between guidelines and practice.
Former Chief of Cardiac Surgery. Decades of experience in cardiovascular care and a firsthand understanding of the downstream consequences of unmanaged lipids.
Leads product, engineering, and operations. Built the clinical decision engine, cloud infrastructure, and HIPAA-compliant platform from the ground up.
Clinical Advisory Board — CardioNexa is guided by an advisory board of practicing cardiologists who validate our clinical logic, review guideline updates, and ensure every recommendation meets the standard of care.
Patient data security isn't a feature — it's the foundation. Every architectural decision prioritizes PHI protection.
AWS infrastructure with AES-256 encryption at rest, TLS 1.2+ in transit, per-client isolation, and a signed BAA with every cloud provider.
Pursuing SOC 2 Type II certification with continuous monitoring. Formal policies, quarterly access reviews, and automated evidence collection.
TOTP multi-factor authentication required for all users. 15-minute idle timeout, 8-hour absolute session limit, and session-level audit tracking.
Every PHI access, view, export, and action logged with user identity, timestamp, and IP address. 6-year retention per HIPAA requirements.
See how CardioNexa can improve LDL-C goal attainment across your ASCVD population.